<DOC>
	<DOC>NCT02066415</DOC>
	<brief_summary>To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention</brief_title>
	<detailed_description>Phase 2, multicenter, randomized, double-blind, placebo-controlled study of patients with chronic migraine. Approximately 651 subjects will be randomized to receive either placebo, or one of two AMG 334 subcutaneous (SC) doses every month for the duration of the 12-week double-blind treatment phase. There will also be safety follow-up visit after the treatment phase.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History of at least 5 attacks of migraine without aura and/or migraine with visual sensory, speech and/or language, retinal or brainstem aura. History of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by the subject as migraine day. ≥ 4 distinct headache episodes, each lasting ≥ 4 hours OR if shorter, associated with use of a triptan or ergotderivative on the same calendar day based on the eDiary calculations. Demonstrated at least 80% compliance with the eDiary. History of cluster headache or hemiplegic migraine headache Unable to differentiate migraine from other headaches Failed &gt; 3 medication categories due to lack of efficacy for prophylactic treatment of migraine . Received botulinum toxinin head or neck region within 4 months prior to screening. Used a prohibited migraine prophylactic medication, device or procedure within 2 months prior to the start of the baseline phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic Migraine</keyword>
</DOC>